Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner.

And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents.